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ABSTRACT
Objective: To investigate the effect of distance between
home and acute hospital on mortality outcome of patients
experiencing an incident myocardial infarction (MI).
Design: Cohort study using a record linkage database.
Setting: Tayside, Scotland, UK.
Patients: 10 541 patients with incident acute MI
between 1994 and 2003 were identified from Tayside
hospital discharge data and from death certification data.
Main outcome measures: MI mortality in the commu-
nity, all-cause mortality in hospital and all-cause mortality
during follow-up.
Results: 4133 subjects died following incident MI in the
community (that is, were not hospitalised), 6408 patients
survived to be hospitalised and 1010 of these (15.8%)
died in hospital. Of 5398 discharged from hospital, 1907
(35.3%) died during a median of 3.2 years of follow-up.
After adjustment for rurality and other known risk factors,
distance between home and admitting hospital was
significantly associated with increased mortality both
before hospital admission (adjusted odds ratio (OR), 2.05,
95% CI 1.00 to 4.21 for .9 miles and 1.46, 1.09 to 1.95
for 3–9 miles when compared to ,3 miles) and after
hospitalisation (adjusted hazard ratio (HR) 1.90, 1.19 to
3.02 and 1.27, 0.96 to 1.68). However, there was no
effect of distance on in-hospital mortality (adjusted OR
0.95, 0.45 to 2.03 and 1.02, 0.66 to 1.58).
Conclusion: The distance between home and hospital of
admission may predict mortality in subjects experiencing
a first acute MI. This association was found both before
and after hospitalisation. Further studies are needed to
explore the reasons for this association. However these
data provide support for policies that locate services for
acute MI closer to where patients live.
Geographical inequalities in care in the UK
National Health Service (NHS) may relate to the
physical distance between patients and NHS
facilities. In Scotland, official policy in the govern-
ment’s response to the Kerr report, supports the
greater provision of acute services in the commu-
nity.
12Geographical inequality for patients with
myocardial infarction (MI) may be related to time
to thrombolysis as it is established that early
thrombolysis and cardiopulmonary resuscitation
improve the mortality outcome.
34 Geographical
inequality could also be explained by more stoical
behaviour of subjects in a rural setting or other
factors. We have done a large population-based
study to investigate the effect of distance between
home and acute hospital on mortality outcome of
patients experiencing an incident MI.
METHODS
The study was carried out in Tayside, Scotland,
using the Medicines Monitoring Unit’s record-
linkage database. The database covers a population
of approximately 400 000 within a geographical
area of approximately 4600 square miles. The data
collection methods for this database have pre-
viously been described.
5 In brief, it contains several
datasets including all dispensed community pre-
scriptions, hospital discharge data, biochemistry
results and other datasets that are linked by a
unique patient identifier, the community health
number. Diagnoses have been validated by inspec-
tion of the general practitioner (GP) records.
6 These
data are anonymised for the purposes of research.
The project was approved by the Tayside Caldicott
Guardians who are appointed by the government
to protect the confidentiality of medical records
and the Tayside committee on research medical
ethics.
Patient population
The study population included subjects who were
resident in Tayside and registered with a GP in
January 1994 and remained in Tayside until
December 2003 or died during the study period—
a fixed population (n=347 131). Study subjects
were patients experiencing an incident MI who
had not previously been hospitalised with a
diagnosis of acute MI between January 1994 and
December 2003.
Prehospital coronary mortality
We studied patients who died out-of-hospital with
a primary certified cause of death (data from the
General Register Office for Scotland) of MI (ICD-9
code 410 and ICD-10 code I21).
Patients hospitalised with MI and follow-up mortality
Patients admitted to Tayside hospitals with their
first MI were identified from the Tayside hospital
discharge data using the primary diagnosis ICD-9
code of 410 and ICD-10 code I21. We tracked the
all-cause mortality of patients during their hospital
stay and following discharge from hospital.
Distance between home and hospital of admission
Distance between home and hospital of admission
was calculated based on the grid reference of the
postcode of the patient’s address and the grid
reference of the address of the admitting hospital.
For patients who died outside hospital the grid
reference of their nearest acute hospital was used
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hospital of admission. The thrombolytic treatment strategy for
Tayside during the study period was in-hospital initiation of
treatment. About half of the patients lived within 5 miles
(8 km) from these hospitals and 98.5% patients lived within
25 miles. The distance between home and hospital was thus
categorised into tertiles: (1) distance ,3 miles; (2) distance
between 3–9 miles; (3) distance .9 miles. We obtained a
rurality code from patient postcodes (that is, urban and rural
classification of postcodes for Scotland, a code of 1 means large
urban area with settlement of over 125 000 people and a code of
8 means very remote rural area with settlement of fewer than
3000 people with a drive time of over 60 minutes to a
settlement of 10 000 or more).
7 We also calculated the travel
time by car along the road network, the car speed being based
on the speed limit for the different types of road.
Thrombolysis data
Three major hospitals (Ninewells Hospital, Perth Royal
Infirmary and Stracathro Hospital) in Tayside provided acute
services. All these hospitals had coronary care units and
accredited cardiologists working in them. However, catheter
laboratory facilities were available only at Ninewells Hospital.
In-hospital thrombolysis data were available for Ninewells
Hospital between December 2001 and December 2004
(n=366). We used these data in a subgroup analysis of patients
to access the impact of thrombolysis on outcome.
Postmortem examination for community MI death
Data were obtained from the General Register Office for those
patients who had been certified as an MI death in the
community and who also had a subsequent postmortem
examination. These subjects were more likely to be those in
whom there was some diagnostic uncertainty and many of
these post mortems were carried out for medicolegal reasons.
Study outcome
The outcome was the individual components: prehospital MI
mortality, in-hospital all-cause mortality and follow-up all-
cause mortality until 31 December 2003.
Statistical analysis
Patients’ characteristics were summarised as mean (SD) for
continuous variables and number of subjects (%) for categorical
variables. The x
2 and t tests were performed to determine
significant differences between dead and alive patients. The
Scottish 2000 standard population was used to calculate the age-
standardised mortality rates. A logistic regression model was used
to estimate the effects of distance between home and hospital of
admission for both prehospital mortality and in-hospital mortal-
ity. Survival analysis was used to estimate the effects of distance
between home and hospital of admission for post-hospital
mortality since patients had different follow-up times. The
results were adjusted for demographic information including
age,gender,Carstairsdeprivation score(derivedfrom thepatients’
postcode and census data comprising social class, overcrowding,
male unemployment and non-car ownership
8), other covariates
including day of week of admission,
9 diabetes mellitus, and
cardiovascular drug use (lipid-lowering drugs, antiplatelet drugs,
b-blockers, angiotensin-converting enzyme (ACE) inhibitors,
diuretics, nitrates, a-blockers, calcium blockers), interactions
between distance and social deprivation or gender and estimated
travel time and rurality. All statistical analyses were carried out
using SAS version 8.2 (SAS institute, Cary, NC, USA).
RESULTS
This study included 10 541 patients (fig 1). Table 1 shows the
characteristics of the patients. The estimated median travel
times by car from home and admitted hospital were 5.9 minutes
(interquartile range (IQR) 3.3–8.9), 15.2 minutes (IQR 11.4–
18.2) and 37.1 minutes (IQR 30.2–41.1) for the short, medium
and long-distance groups, respectively.
Prehospital mortality
In all, 4133 patients with MI as the primary certified cause of
death died without being hospitalised or before they reached a
hospital (table 1). The age-adjusted death rate was 8.4% (8.0%
for men and 9.3% for women); 50.9% of patients were women
and 35.1% of patients lived .9 miles from the hospital.
Compared with patients living ,3 miles from hospitals those
living .3 miles from hospital had higher MI mortality (adjusted
OR 1.46, 95% CI 1.09 to 1.95 for 3–9 miles and 2.05, 1.00 to 4.21
for .9 miles).
Diagnostic accuracy of community MI death
About 10% of patients certified as a community MI death had
postmortem examinations. The postmortem results showed
that MI was the cause of death in over 95% of these subjects
during the study period.
In-hospital mortality
A total of 6408 patients (57.9% male) survived to be hospitalised
with incident acute MI during the study period and 1010 of
these (15.8%) died in hospital (that is, case fatality). The median
duration of hospitalisation was 2 days. Except for b-blocker use
patients who died in hospital had received more cardiovascular
drug prescriptions in the previous year than patients who
survived. There were significant differences in gender, age and
social deprivation between patients who survived and those
who died. Women and older patients had higher risk of
mortality than men and young patients. The age-adjusted
death rate was 11.6% (12.3% for men and 10.8% for women).
There were more women living closer to hospital than men. The
percentages of women in each distance category were 36.2%,
Figure 1 Flow chart of patients in the study.
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groups, respectively.
There was no increased risk of death in hospital with
increasing distance between home and hospital of admission
(table 2).
Follow-up mortality
In all, 5398 patients (3260 men, 2128 women) were discharged
from hospital and were followed up for a median of 3.2 years
(IQR 1.1–6.2). Of these, 1907 patients (35.3%, 1017 men and
890 women) died during the follow-up period. The age-adjusted
death rate was 8.6% (8.4% for men and 9.4% for women). There
was a significantly increased use of statins and other cardio-
vascular drugs following hospitalisation compared with pre-
vious drug use (table 1). Patients who survived during follow-up
had higher prescribing rates for cardiovascular drugs than
patients who died (as we have shown before).
10 A total of
3214 patients (59.5%) were taking lipid-lowering drug treat-
ment and, of these, 3194 (99.4%) were taking statin treatment.
After adjustment for other risk factors, patients who lived
.9 miles from the hospital had an increased risk of mortality
during the follow-up period when compared to patients who
lived ,3 miles from the hospital (adjusted HR 1.90, 95% CI 1.19
to 3.02) (table 2). A non-significant increased mortality was
seen for those who lived 3-9 miles from the hospital (adjusted
HR 1.27, 95% CI 0.96 to 1.68).
Effect of cardiovascular drugs
Compared with non-users, users of lipid-lowering drugs
(adjusted HR 0.47, 95% CI 0.42 to 0.53), antiplatelet drugs
(adjusted HR 0.40, 95% CI 0.35 to 0.45), b-blockers (adjusted
HR 0.55, 95% CI 0.49 to 0.62) and ACE inhibitors (adjusted HR
0.84, 95% CI 0.75 to 0.93) during the follow-up had a
significantly lower risk of mortality.
Thrombolysis
A total of 209 out of 5398 (3.8%) patients had thrombylosis data
for the follow-up analysis. This subgroup analysis suggested
Table 1 Characteristics of patients following myocardial infarction, Tayside
Prehospital In-hospital Post-hospital
Dead Dead Alive Dead Alive
No % No % No % No % No %
Distance (miles){
,3 1287 31.7 407 41.6 1753 33.0** 678 36.5 1075 31.1**
3–9 1346 33.2 304 31.0 1801 33.9 607 32.7 1194 34.6
.8 1423 35.1 268 27.4 1756 33.1 572 30.8 1184 34.3
Sex
Male 2029 49.1 443 43.9 3270 60.6** 1017 53.3 2253 64.5**
Female 2104 50.9 567 56.1 2128 39.4 890 46.7 1238 35.6
Age (mean, SD) 77.2 10.9 78.5 9.6 67.5 12.6** 74.6 10.2 63.7 12.1**
Deprivation category{
1, least deprived 175 4.4 47 4.8 313 5.9 100 5.4 213 6.1
2 833 20.9 172 17.4 980 18.4 325 17.6 655 18.8
3 1187 29.8 312 31.6 1508 28.3 502 27.3 1006 28.8
4 424 10.7 122 12.3 561 10.5 216 11.7 345 9.9
5 487 12.2 111 11.2 648 12.2 221 12.0 427 12.2
6+, most deprived 876 23.0 225 22.8 1320 24.8 478 26.0 742 24.1
Travel time (mean, SD) – – 17.3 15.3 19.3 14.9** 20.4 15.7 18.7 15.4**
Urban-rural code{
1 1603 40.5 385 38.6 2356 44.0** 813 43.5 1543 44.2
2 1003 25.4 289 29.0 1410 26.3 527 28.2 883 25.3
3, 6 1181 29.9 280 18.0 1431 26.7 467 25.0 964 27.6
7, 8 167 4.2 44 4.4 163 3.0 62 3.3 101 2.9
Previous hospitalisation
Angina 445 10.8 121 12.0 691 12.8 295 15.5 396 11.3**
Heart failure 845 20.5 277 27.4 1402 26.0** 821 43.1 581 16.6**
Stroke 433 10.5 111 11.0 271 5.0** 173 9.1 98 2.8**
Hypertension 432 10.5 131 13.0 645 12.0* 233 12.2 412 11.8**
PVD 462 11.2 128 12.7 423 7.8** 232 12.2 191 5.5**
Diabetes 567 13.7 146 14.5 715 13.2 327 17.2 388 11.1**
Cardiovascular drug use in the previous year{
Lipid-lowering drug 325 7.9 97 9.6 667 12.4* 554 29.1 2660 76.2**
Antiplatelets 1569 38.0 386 38.2 1556 28.8** 1205 63.2 2907 83.3**
b-blockers 1148 27.8 302 29.9 1684 31.2 539 28.3 2264 64.9**
ACE inhibitors 868 21.0 188 18.6 787 14.6** 765 40.1 2054 58.8**
Diuretics 2570 62.2 628 62.2 2110 39.1** 1052 55.2 1388 39.8**
a-blockers 198 4.8 56 5.5 257 4.8** 54 2.8 123 3.5
Nitrates 1438 34.8 374 37.0 1627 30.1** 1047 54.9 2435 69.8**
Ca-blockers 1370 33.2 370 36.6 1694 31.4 518 27.2 1177 33.7**
Data are numbers and percentages unless otherwise stated.
*Comparison of dead and alive patients, p,0.05; **p,0.01. {Excluding missing data. {Drug uses during the follow-up for post-hospital cohort.
ACE, angiotensin-converting enzyme; PVD, peripheral vascular disease.
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95% CI 0.37 to 1.07), However, early thrombolysis did not
change the direction of the impact of distance (adjusted HR
1.86, 95% CI 0.49 to 7.02 for patients who lived 3–9 miles from
the hospital, adjusted HR 1.43, 95% CI 0.18 to 11.39 for patients
who lived .9 miles from the hospital when compared with
patients who lived ,3 miles from the hospital).
DISCUSSION
Previous studies have shown a relation between the treatment
delay and mortality outcome in MI patients.
11–14 However, few
studies have investigated the impact of geographical location
and none has been representative of a complete population.
15
Our data suggest that the distance between home and hospital
of admission predicts mortality in subjects experiencing first
acute MI both in the community (prehospital) and following
discharge from hospital after adjustment for urban-rural code or
travel time and other covariates. There was no difference if
these results were adjusted only for age, sex and other
covariates, suggesting that urban-rural code and travel time
are the significant confounders. Other areas that could cause a
delay between the onset of symptoms and treatment are the
delay by patients in calling for help and the delay between
calling for help and the attendance of a doctor. We could not
measure these but they could be investigated.
16 However, we
used a measure of rurality as a possible surrogate measure of
patient behaviour in the different geographical settings.
The median travel time was 37 minutes for patients who
lived .9 miles from an acute hospital. This time does not
include time taken for the ambulance to reach the patient. In
addition, these times take no account of adverse traffic or
weather conditions. We think that it is unlikely that this group
of patients could have met the national target for thrombolysis
within 60 minutes of a call for help.
Geographical inequality and early thrombolysis
Our data support the concept that there is geographical
inequality of care in patients who have had an acute incident
MI. An excess in coronary heart disease (CHD) death rates in
young patients was reported outside the state capital cities in
Australia.
17 The risk factors between the populations and
inadequacies in the level of medical care provided were the
two main reasons that have been used to explain this excess
CHD death. A recent US study showed that a mile increase in
distance leads to a nearly 6.5% increase in the number of deaths
from a heart attack.
18 However in Scotland, the National Health
Service is tax funded, free at the point of consumption and
covers the entire population. There should thus be no socio-
economic eligibility distinctions in the level of health care given
to an individual, being based on need alone. One hypothesis is
that the time delay related to distance plays an important part
in the prognosis of MI patients. A study from our own region
demonstrated that an early thombolysis treatment strategy was
achievable and improved outcome.
19 However when we
Table 2 Adjusted odds ratios (OR) or hazard ratios (HR) for mortality in patients with MI
Prehospital In-hospital Post-hospital
Number of event/total
Distance (miles), tertile*
,3 1287/3447 407/2160 678/1753
3–9 1346/3451 304/2105 607/1801
.9 1423/3447 268/2024 572/1756
OR or HR
OR (95% CI) OR (95% CI) HR (95% CI)
Unadjusted
,3 1.00 1.00 1.00
3–9 1.07 (0.97 to 1.18) 0.73 (0.62 to 0.86) 0.83 (0.74 to 0.92)
.9 1.18 (1.07 to 1.30) 0.66 (0.56 to 0.78) 0.88 (0.79 to 0.98)
Adjusted for age, sex and deprivation
,3 1.00 1.00 1.00
3–9 1.17 (1.05 to 1.30) 0.80 (0.66 to 0.95) 0.89 (0.79 to 1.00)
.9 1.20 (1.07 to 1.35) 0.63 (0.52 to 0.77) 0.96 (0.86 to 1.10)
Adjusted for age, sex, deprivation and other covariates
,3 1.00 1.00 1.00
3–9 1.16 (1.04 to 1.29) 0.82 (0.68 to 0.98) 0.90 (0.80 to 1.01)
.9 1.18 (1.05 to 1.32) 0.66 (0.54 to 0.80) 0.97 (0.85 to 1.10)
Adjusted for age, sex, deprivation, other covariates and urban-rural code
,3 1.00 1.00 1.00
3–9 1.21 (1.07 to 1.37) 1.07 (0.73 to 1.58) 1.21 (0.95 to 1.54)
.9 1.30 (1.10 to 1.54) 0.79 (0.44 to 1.40) 1.49 (1.04 to 2.15)
Adjusted for age, sex, deprivation, other covariates and estimated travel time
,3 1.00 1.00 1.00
3–9 1.44 (1.16 to 1.78) 0.65 (0.44 to 0.98) 1.19 (0.90 to 1.58)
.9 2.37 (1.24 to 4.54) 1.04 (0.22 to 4.93) 2.06 (1.01 to 4.21)
Adjusted for age, sex, deprivation, other covariates, urban-rural code and estimated travel time
,3 1.00 1.00 1.00
3–9 1.46 (1.09 to 1.95) 1.02 (0.66 to 1.58) 1.27 (0.96 to 1.68)
.9 2.05 (1.00 to 4.21) 0.95 (0.45 to 2.03) 1.90 (1.19 to 3.02)
*Other covariates included day of week of admission, previous cardiovascular disease, diabetes mellitus, cardiovascular drug use
and interactions between distance and deprivation/sex. Analysis was done by excluding missing data.
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between distance from acute facilities and mortality.
A US Veteran Affairs (VA) study investigated the effect of
distance between home and hospital of admission on mortality
in male post-MI patients.
15 They compared the mortality
outcome between patients (64%) who lived more than 20 miles
from any VA health source and patients (36%) who lived within
20 miles. They found a positive relation between distance and
follow-up mortality. However they studied only men and their
results may not be generalisable to other healthcare systems.
Our study indicates that the distance from home to hospital of
admission is an important factor that predicts survival follow-
ing acute MI.
Study limitations and strengths
There are some limitations in our study. First, we did not have
information on smoking, obesity, severity of MI, invasive
management after discharge, the treating specialist at the
admitting hospital and other unmeasured risk factors, all of
which are likely to be important in patients with heart disease.
However, we did use the Carstairs socioeconomic deprivation
score as a surrogate measure for at least some of these
factors.
20 21 Also, our previous sensitivity analysis on unmea-
sured risk factors showed that at least some of these unknown
risk factors were unlikely to make a big impact on cardiovas-
cular outcome.
22 Second, the distance we used in this study was
based on home and hospital addresses. We did not know the
exact location of the patients when they had a heart attack.
However, given the average age of 72, we would expect that the
majority of patients would have had their MI at or near their
home. Third, we did not have information on the time of onset
of MI symptoms. Fourth, we used linear distance and estimated
travel time in the study. However, distance along the road
network may be different and there may have been differences
in traffic conditions at different times of day.
We observed independent risk reductions in mortality during
the follow-up period for lipid-lowering drugs, antiplatelet drugs
and b-blockers consistent with the finding from clinical trials
and other observational studies.
23–28 However we may have
underestimated the benefits of cardiovascular drugs because we
assumed all patients complied with their drug treatment when
in reality this is rarely the case.
28 Finally, the diagnostic accuracy
of MI death before hospitalisation is open to question. The data
retrieved from the General Register Office revealed that in those
subjects who had postmortem examinations performed, the
diagnosis of MI was almost always confirmed. Presumably
those subjects who underwent post mortems were those in
whom the diagnosis was in question and was more likely to be
incorrect. Thus these postmortem data are reassuring and
suggest that prehospital MI death data were reasonably
accurate.
The strength of our study is the population-based cohort
design, with complete follow-up over the study period. This
approach allows a ‘‘real-world’’ population to be studied,
representing all socioeconomic groups and within a universal
healthcare coverage scheme.
29 The results inform us that there
may be geographical inequality in healthcare delivery, the cause
of which is currently difficult to explain. This relation may
influence healthcare policy on the provision of prehospital care
such as thrombolysis for MI, the enhanced provision of
paramedics and the greater delivery of ambulance services to
remote communities. It is in line with the recent Kerr report in
Scotland calling for services to be delivered closer to patients
wherever possible,
30 and studies demonstrating that managed
clinical networks can achieve this goal.
31
In conclusion, our data suggested that distance from home to
hospital may predict mortality outcome in subjects experiencing
an acute MI. These data provide support for policies that locate
services for acute MI closer to where patients live.
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